US FDA approves Ionis therapy Zanvastro for rare brain disorder
The U.S. FDA approved Ionis Pharmaceuticals’ zilganersen (Zanvastro) to treat a rare genetic disorder affecting the brain’s white matter, with use for adults and pediatric patients.
The U.S.
FDA on Thursday approved Ionis Pharmaceuticals' NASDAQ:IONS therapy to treat a rare disease that affects the brain's white matter, making it the first treatment to get the nod for the genetic disorder.Ionis' drug zilganersen, branded as Zanvastro, can be used to treat adults and pediatric…